Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Pruritus Therapeutics Market, by Disease Type
1.4.2 North America Pruritus Therapeutics Market, by Product
1.4.3 North America Pruritus Therapeutics Market, by Distribution Channel
1.4.4 North America Pruritus Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Force Analysis
Chapter 4. North America Pruritus Therapeutics Market by Disease Type
4.1 North America Atopic Dermatitis Market by Country
4.2 North America Allergic Contact Dermatitis Market by Country
4.3 North America Urticaria Market by Country
4.4 North America Others Market by Country
Chapter 5. North America Pruritus Therapeutics Market by Product
5.1 North America Corticosteroids Market by Country
5.2 North America Antihistamines Market by Country
5.3 North America Local Anesthetics Market by Country
5.4 North America Counterirritants Market by Country
5.5 North America Immunosuppressant Market by Country
5.6 North America Calcineurin Inhibitors Market by Country
5.7 North America Others Market by Country
Chapter 6. North America Pruritus Therapeutics Market by Distribution Channel
6.1 North America Drug Stores & Retail Pharmacies Market by Country
6.2 North America Hospital Pharmacies Market by Country
6.3 North America Online Providers Market by Country
Chapter 7. North America Pruritus Therapeutics Market by Country
7.1 US Pruritus Therapeutics Market
7.1.1 US Pruritus Therapeutics Market by Disease Type
7.1.2 US Pruritus Therapeutics Market by Product
7.1.3 US Pruritus Therapeutics Market by Distribution Channel
7.2 Canada Pruritus Therapeutics Market
7.2.1 Canada Pruritus Therapeutics Market by Disease Type
7.2.2 Canada Pruritus Therapeutics Market by Product
7.2.3 Canada Pruritus Therapeutics Market by Distribution Channel
7.3 Mexico Pruritus Therapeutics Market
7.3.1 Mexico Pruritus Therapeutics Market by Disease Type
7.3.2 Mexico Pruritus Therapeutics Market by Product
7.3.3 Mexico Pruritus Therapeutics Market by Distribution Channel
7.4 Rest of North America Pruritus Therapeutics Market
7.4.1 Rest of North America Pruritus Therapeutics Market by Disease Type
7.4.2 Rest of North America Pruritus Therapeutics Market by Product
7.4.3 Rest of North America Pruritus Therapeutics Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Bristol Myers Squibb Company
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 SWOT Analysis
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 Pfizer, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Approvals:
8.3.6 SWOT Analysis
8.4 Sanofi S.A.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 SWOT Analysis
8.5 Astellas Pharma, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Cara Therapeutics, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.6.4 Recent strategies and developments:
8.6.4.1 Partnerships, Collaborations, and Agreements:
8.6.5 SWOT Analysis
8.7 GlaxoSmithKline PLC (GSK)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Teva Pharmaceutical Industries Ltd.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 SWOT Analysis
8.9 Amgen, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. AbbVie, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Approvals & Trials:
8.10.6 SWOT Analysis
Unique Offerings 